Login

AVEO PHARMACEUTICALS, INC. SEC Filings

Filed On Filing
30 Jan 2023 15-12G
23 Jan 2023 EFFECT
23 Jan 2023 EFFECT
23 Jan 2023 EFFECT
19 Jan 2023 Form 4: Bate Kenneth, Director

Returned 375 shares to the issuer ($5.63K) · Disposed of 68,202 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Evnin Anthony B, Director

Returned 41,841 shares to the issuer ($628K) · Disposed of 68,202 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Ledell Jebediah, Chief Operating Officer

Disposed of 197,702 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Ferraresso Michael, Chief Commercial Officer

Returned 16,345 shares to the issuer ($245K) · Disposed of 421,312 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Epperly Corinne, Director

Disposed of 47,500 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Cullen Kevin Joseph, Director

Disposed of 47,500 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Spring Scarlett, Director

Disposed of 49,000 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Mayes, Gregory T., Director

Disposed of 49,000 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Bailey Michael P, Director

Returned 333,167 shares to the issuer ($5M) · Disposed of 1,379,956 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 Form 4: Lucera Erick, Chief Financial Officer

Disposed of 368,800 Stock Option (Right to Buy) (Disposition to Issuer)

19 Jan 2023 25-NSE
19 Jan 2023 POS AM
19 Jan 2023 POS AM
19 Jan 2023 POS AM
19 Jan 2023 S-8 POS
19 Jan 2023 S-8 POS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support